Magellan Health, Inc. $400 Million Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of $400 million aggregate principal amount of 4.400% senior notes due…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Zai Lab Limited Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $172.5 million initial public offering by Zai Lab Limited of 9,583,333 American…
Healthcare Trust of America, Inc. $500 Million At-the-Market Offering
Davis Polk advised the forward purchasers and forward sellers in connection with an at-the-market forward underwriting program for the offer and sale of shares of Class A common stock…
Portola Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers and the co-managers in connection with the $349.3 million public offering of common stock by Portola Pharmaceuticals, Inc. The…
Zoetis Inc. $1.25 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $750 million aggregate principal amount of its 3.000% senior…
Jazz Pharmaceuticals $500 Million Exchangeable Senior Notes Offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $500 million aggregate…
Oxford Immunotec Global PLC Offering of Ordinary Shares
Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary shares of Oxford Immunotec Global PLC. The ordinary shares are…
BeiGene, Ltd. Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public offering by BeiGene, Ltd. of American Depositary Shares. The ADSs…
Celgene $500 Million Notes Offering
Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. …
Spark Therapeutics Follow-On Offering
Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The…